Cary Business: Ockham Acquires Nexus

Story from staff reports. Scanning electron micrograph by Anne Weston for  Wellcome Industries.

Cary, NC – The high-tech focus of Cary business continues to expand with the acquisition of Nexus Oncology by Ockham, a Cary company.

Ockham – Contract Medical Research

Ockham, headquartered at 8000 Regency Parkway, is a Contract Research Organization (CRO). They test new medicines, medical devices, pharmaceutical manufacturing and a host of other clinical applications.

Nexus describes itself as a niche oncology CRO. Ockham’s Chief Executive Officer, James V. Baker, will run the combined company. The organization released this info:

In combining with Nexus, Ockham now employs almost 300 employees across 12 countries, placing it among top-tier niche CROs worldwide.  This merger offers a greater global scale and depth of oncology-specific knowledge.  The new organization is now more strongly positioned in the field of oncologic clinical trials.